- Home
- VICR vs BLTE Comparison
VICR vs BLTE Comparison
Compare VICR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VICR | BLTE |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | VICR | BLTE |
|---|---|---|
| Price | $141.65 | $158.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $102.50 | ★ $156.00 |
| AVG Volume (30 Days) | ★ 595.2K | 250.7K |
| Earning Date | 02-19-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1696.11 | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | ★ $441,603,000.00 | N/A |
| Revenue This Year | $28.74 | N/A |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $75.23 | ★ N/A |
| Revenue Growth | ★ 24.20 | N/A |
| 52 Week Low | $38.93 | $49.00 |
| 52 Week High | $149.99 | $170.25 |
Technical Indicators
Market Signals| Indicator | VICR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 81.18 | 56.72 |
| Support Level | $130.86 | $153.56 |
| Resistance Level | $149.99 | $170.25 |
| Average True Range (ATR) | 7.94 | 6.34 |
| MACD | 3.00 | -1.18 |
| Stochastic Oscillator | 86.79 | 28.64 |
Price Performance
Historical ComparisonAbout VICR Vicor Corporation
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.